Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 6

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 1
Chunk 6
---
199,859)
  
    Adjustments
    to reconcile net income (loss) to net cash used in operating activities: 

    Payment
    of operating costs through promissory note 
     114,676  
     20,300 
  
    Interest
    earned on cash and investments held in Trust Account 
     (6,454,232) 
     — 
  
    Changes
    in operating assets and liabilities: 

    Prepaid
    expenses 
     (27,479) 
     — 
  
    Accounts
    payable and accrued expenses 
     225,343  
     7,400 
  
    Net
    cash used in operating activities 
     (414,007) 
     (172,159)

    Cash
    Flows from Investing Activities: 

    Investment
    of cash into Trust Account 
     (231,150,000) 
     — 
  
    Net
    cash used in investing activities 
     (231,150,000) 
     — 

    Cash
    Flows from Financing Activities: 

    Proceeds
    from sale of Units, net of underwriting discounts paid 
     228,850,000  
     — 
  
    Proceeds
    from issuance of Class B ordinary shares to Sponsor 
     —  
     35,000 
  
    Proceeds
    from promissory note - related party 
     —  
     1,702,663 
  
    Proceeds
    from sale of Private Placement Units 
     3,200,000  
     — 
  
    Expenses
    paid by Sponsor under share subscription receivable 
     410,178  
     — 
  
    Repayment
    of promissory note - related party 
     (900,000) 
     (1,200,448)
  
    Payment
    of offering costs 
     3,195  
     (362,961)
  
    Net
    cash provided by financing activities 
     231,563,373  
     174,254 

    Net
    Change in Cash 
     (634) 
     2,095 
  
    Cash
    – Beginning of period 
     1,351  
     — 
  
    Cash
    – End of period 
    $717